Q-Sera Pty Ltd, an Australian venture-backed company, has launched its patented evacuated blood collection technology in Japan through a partnership with Terumo Corporation, a Japanese medical device company. The launch of Terumo’s VenoJect II RAPClotTM blood collection tubes in the Japanese market marks the first product launch of Q-Sera’s patented Rapclot technology, paving the way for potential global partnerships.
Q-Sera’s Rapclot technology is designed to improve the efficiency and safety of blood collection, a crucial step in medical diagnosis and treatment. The company’s innovative approach has garnered significant attention in the medical device industry, with several major players expressing interest in integrating the technology into their products. As a result, Q-Sera has established partnerships with key industry players, including Terumo Corporation, to bring its technology to market.
The launch of VenoJect II RAPClotTM blood collection tubes in Japan is a significant milestone for Q-Sera, as it marks the company’s entry into the global market. The Japanese market is highly competitive, with major players such as Medtronic and Becton Dickinson already established. However, Q-Sera’s partnership with Terumo Corporation, a leading Japanese medical device company, is expected to provide a significant boost to the company’s growth prospects.
The global blood collection market is projected to grow significantly in the coming years, driven by increasing demand for diagnostic testing and the need for more efficient and safe blood collection methods. According to a report by Grand View Research, the global blood collection market is expected to reach $6.4 billion by 2028, growing at a CAGR of 5.5%. The market is highly competitive, with several major players competing for market share. The following table highlights the key players in the global blood collection market:
| Company | Market Share |
|---|---|
| Becton Dickinson | 23.1% |
| Medtronic | 18.5% |
| Terumo Corporation | 12.1% |
Looking ahead, Q-Sera’s launch in Japan is expected to be followed by additional launches in other markets, as the company seeks to establish itself as a leader in the global blood collection market. With its patented Rapclot technology and partnerships with key industry players, Q-Sera is well-positioned to capitalize on the growing demand for efficient and safe blood collection methods.
⚡ Why it matters: Q-Sera’s launch in Japan marks a significant milestone in the company’s growth prospects and highlights the potential for its patented Rapclot technology to disrupt the global blood collection market. The company’s partnerships with key industry players, such as Terumo Corporation, are expected to drive growth and expansion into new markets.
📊 By the numbers:
$6.4 billion: projected global blood collection market size by 2028
5.5%: projected CAGR for the global blood collection market
23.1%: Becton Dickinson’s market share in the global blood collection market
🔗 Source: GlobeNewswire*
